CClinicalTrials.gg
Status unknownNCT02829164Updated May 23, 2017

Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region

An observational study in Tonsillectomy, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
20
Ages
Up to 18 Years
Sex
All
01

Study summary

Primitive kidney disease IgA, represented by Berger's disease and rheumatoid purpura nephropathy, are the first cause of kidney failure from chronic glomerulonephritis: changes in 20 years to end-stage renal failure is described in 10 to 30 % of cases in Berger's disease and in 15 to 20% of cases in nephropathy HSP. These two pathological entities share biological and histological characteristics, as well as common pathophysiological mechanisms, particularly the production of abnormally glycosylated IgA1 promoting their proliferation in the mesangium. Tonsils part of Iga abnormal production sites that would be associated with an infectious stimulus, tonsillectomy has been studied as a possible treatment in primitive IgA nephropathy. The benefit of tonsillectomy is controversial: many Japanese studies demonstrate its effectiveness in terms of reduction of proteinuria, improved renal function in the long term regression of histological lesions and reduced risk of relapse following clinical remission whereas European studies do not suggest its effectiveness in treating IgA nephropathy. In this context, the aim of our study is to describe the scope of practice of tonsillectomy in the treatment of primary renal disease in IgA child in the inter East region and describe the short renal become Strasbourg end of the cohort that received this treatment.

02

Conditions studied

  • Tonsillectomy

Keywords

  • Tonsillectomy
  • primary IgA nephropathy
  • primary nephropathy
  • IgA
  • Berger's disease
  • Purpura rheumatoid
  • kidney failure
03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's planned enrollment of 20 is below the median of 192 across 1,033 observational studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy

Inclusion criteria

  • Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy
  • Follow the University Hospital of Strasbourg since 2009
  • Having received a tonsillectomy in their care
  • Children whose holders of parental authority does not oppose the use of clinical data from their child for research purposes

Exclusion criteria

Exclusion criteria:

  • Children whose holders of parental authority are opposed to the use of clinical data from their child for research purposes
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluation of the management of the tonsillectomy at the CHU of Strasbourg by a standardized questionnaire

    Time frame: since January 2009

07

Study locations

1 of 1 sites recruiting
  • Service de Pédiatrie 1 Hôpital de Hautepierre
    Strasbourg, 67098, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02829164
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 12, 2016
Start date
Apr 2016
Primary completion
Sep 2017 (estimated)
Completion
Sep 2017 (estimated)
Last update
May 23, 2017

Study contacts

Laetitia HIGEL, MD
Contact
laetitia.higel@chru-strasbourg.fr
33 (0)3.88.12.77.40
Eléonore FEUGEAS, MD
Contact
Eleonore.feugeas@chru-strasbourg.fr
33 (0)3.88.12.77.40
Laetitia HIGEL, MD
study director · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion